Sphingolipids are essential components of eukaryotic cell membranes and play critical roles in immunity, inflammation, and inflammatory disorders. Ceramide and sphingosine-1-phosphate (S1P) are key signaling molecules that regulate various cellular processes, including immune cell trafficking, vascular integrity, and inflammation. Recent advances in sphingolipidomics and animal models have revealed their importance in chronic inflammation and disease progression. Sphingolipid metabolism involves the synthesis, modification, and degradation of these molecules, with ceramide being a central player in inflammatory responses. S1P, generated from sphingosine via sphingosine kinases, is a pleiotropic bioactive metabolite that influences immune cell function and vascular integrity. The S1P gradient between blood and tissues is crucial for immune cell trafficking and maintaining endothelial barrier function. Sphingolipid signaling is regulated by various enzymes and receptors, with S1P receptors (S1PR1–S1PR5) playing key roles in immune responses. S1P can act through paracrine and autocrine mechanisms, and its signaling pathways are complex, involving multiple intracellular targets. Sphingolipid metabolism is also linked to inflammatory diseases such as multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, and asthma. Therapeutic interventions targeting sphingolipid metabolism, such as FTY720, have shown promise in treating inflammatory disorders by modulating immune cell trafficking and reducing inflammation. Understanding the molecular mechanisms of sphingolipid signaling and their roles in inflammation is crucial for developing new therapeutic strategies.Sphingolipids are essential components of eukaryotic cell membranes and play critical roles in immunity, inflammation, and inflammatory disorders. Ceramide and sphingosine-1-phosphate (S1P) are key signaling molecules that regulate various cellular processes, including immune cell trafficking, vascular integrity, and inflammation. Recent advances in sphingolipidomics and animal models have revealed their importance in chronic inflammation and disease progression. Sphingolipid metabolism involves the synthesis, modification, and degradation of these molecules, with ceramide being a central player in inflammatory responses. S1P, generated from sphingosine via sphingosine kinases, is a pleiotropic bioactive metabolite that influences immune cell function and vascular integrity. The S1P gradient between blood and tissues is crucial for immune cell trafficking and maintaining endothelial barrier function. Sphingolipid signaling is regulated by various enzymes and receptors, with S1P receptors (S1PR1–S1PR5) playing key roles in immune responses. S1P can act through paracrine and autocrine mechanisms, and its signaling pathways are complex, involving multiple intracellular targets. Sphingolipid metabolism is also linked to inflammatory diseases such as multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, and asthma. Therapeutic interventions targeting sphingolipid metabolism, such as FTY720, have shown promise in treating inflammatory disorders by modulating immune cell trafficking and reducing inflammation. Understanding the molecular mechanisms of sphingolipid signaling and their roles in inflammation is crucial for developing new therapeutic strategies.